Australia - inglese - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ezetimibe, quantity: 10 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; carmellose sodium; povidone; sodium lauryl sulfate; polysorbate 80; magnesium stearate - adults (greater than or equal to 18 years),primary hypercholesterolaemia,ezetimibe administered alone, or with an hmg-coa reductase inhibitor (statin), is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia.,homozygous familial hypercholesterolaemia (hofh),ezetimibe, administered with a statin, is indicated for patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).,homozygous sitosterolaemia (phytosterolaemia),ezetimibe is indicated for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolaemia.,prevention of cardiovascular disease,ezetimibe is indicated for administration in combination with the maximum tolerated dose of a statin with proven cardiovascular benefit in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) in need of additional lowering of ldl-c in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy (see section 5.1 pharmacodynamic properties, clinical trials).,children and adolescents 10-17 years (pubertal status: boys tanner stage ii and above and girls who are at least one year post-menarche),heterozygous familial hypercholesterolaemia (hefh),ezetimibe co-administered with simvastatin (doses up to 40 mg) is indicated as an adjunctive therapy to diet in adolescent patients (10-17 years old) with heterozygous familial hypercholesterolaemia where use of a combination product is appropriate: ? patients not appropriately controlled with a statin or ezetimibe alone ? patients already treated with a statin and ezetimibe,homozygous familial hypercholesterolaemia (hofh),ezetimibe co-administered with simvastatin (doses up to 40 mg) is indicated in adolescent patients (10-17 years old) with hofh. patients may also receive adjunctive treatments (e.g. ldl apheresis)

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - atorvastatin calcium trihydrate - oral tablet - 10mg

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - atorvastatin calcium trihydrate - oral tablet - 10mg

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

dowelhurst ltd - atorvastatin calcium trihydrate - oral tablet - 10mg

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - atorvastatin calcium trihydrate - oral tablet - 10mg

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - atorvastatin calcium trihydrate - oral tablet - 10mg

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

lexon (uk) ltd - atorvastatin calcium trihydrate - oral tablet - 10mg

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - atorvastatin calcium trihydrate - oral tablet - 10mg

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

necessity supplies ltd - atorvastatin calcium trihydrate - oral tablet - 10mg

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - atorvastatin calcium trihydrate - chewable tablet - 10mg